Clinical trials: Refractory or Unexplained Chronic Cough
Chronic Cough
Study of Gefapixant (MK-7264) in Adult Japanese Participants With Unexplained or Refractory Chronic Cough (MK-7264-033)
This estimation study (no hypotheses) will evaluate the safety, tolerability, and efficacy of gefapixant (MK-7264) in Japanese adult participants with unexplained or refractory chronic cough.
- Trial name
- NCT03482713
- Testing
- Gefapixant 45 mg
- Where
- 16 sites in Japan
- Volunteers
- 23 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Cough
A Study of Gefapixant (MK-7264) in Japanese Adult Participants With Refractory or Unexplained Chronic Cough (MK-7264-038)
The primary objective of this study is to evaluate the safety of two doses of gefapixant (MK-7264) in Japanese adult participants with refractory or unexplained chronic cough.
- Trial name
- NCT03696108
- Testing
- Gefapixant
- Where
- 61 sites in Japan
- Volunteers
- 175 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Refractory Cough
A Dose Escalation Study of BLU-5937 in Unexplained or Refractory Chronic Cough
This is a multi-center, randomized, double-blind, placebo-controlled, crossover, dose escalation study of BLU-5937 in subjects with unexplained or refractory chronic cough
- Trial name
- RELIEF (NCT03979638)
- Testing
- BLU-5937
- Where
- 16 sites in United States, United Kingdom
- Volunteers
- 68 people
- Sponsor
- Bellus Health Inc. - a GSK company
Refractory and/or Unexplained Chronic Cough
Clinical Study to Evaluate the Efficacy and Safety of Three Different Doses of BAY1817080 Compared to Placebo in Patients With Chronic Cough
Researchers in this study want to find the optimal therapeutic dose of drug BAY1817080 for patients with long-standing cough with or without clear causes (refractory and/or unexplained chronic cough, RUCC).
- Trial name
- PAGANINI (NCT04562155)
- Testing
- BAY1817080
- Where
- 99 sites in United States, Argentina and 17 more
- Volunteers
- 310 people
- Sponsor
- Bayer